Publication & Date: Journal of Affective Disorders 240:130-136 (2018) Investigators: A Tendler, R Gersner, Y Roth, A ZangenRead More
This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Repetitive transcranial magnetic stimulation (rTMS) has proven effective. Recently, a greater intracranial penetration coil has been developed.
The studytested the efficacy of the coil in the treatment of resistant major depression.
The studysample included seven patients suffering from major depression who were treated using Brainsway’s H1-coil connected to a Magstim rapid 2 stimulator. Deep TMS treatment was given to each patient in five sessions per week over a period of 4 weeks.Patients were treated with 120% intensity of the motor threshold and a frequency of 20 HZ with a total of 1,680 pulses per session.
A significant improvement in HDRS scores was found when high, but not low, stimulation intensity was used. Several cognitive improvements were evident, and no treatment-related serious adverse events were observed.
This study provides additional evidence for the feasibility and safety of the twoH-coil designs (H1/H2). The H-coils offer a safe new tool with potential for both research and clinical applications for psychiatric and neurologicaldisorders associated with dysfunctions of deep brain regions.